PGY2 SOT Gillian Stiger joins us from the Hospital of the University of Pennsylvania to discuss “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”, as well as a discussion on her residency experience with belatacept rapid conversion for a patient with thrombotic microangiopathy associated with tacrolimus.